Search

everythinglearnresearchcommunity

for

Search:↓

Premature hair graying may be a sign of increased risk for heart disease, indicating biological age is more important than actual age.

PCOS may increase the risk of certain cancers.

PCOS is linked to a higher risk of endometrial cancer but not ovarian or breast cancer, and more research is needed on its role in cancer development and treatment effects.

The document concludes that future heart disease research should account for sex-specific differences to improve diagnosis, treatment, and outcomes.

Taking 5-α reductase inhibitors for prostate enlargement or hair loss does not significantly raise the risk of erectile dysfunction.

Valproic acid increases the risk of hair loss more than other drugs, especially in migraine patients, and lamotrigine may be a safer alternative.

Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.

The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

Hyperandrogenism increases heart disease risk in premenopausal women, but this risk is linked to obesity in postmenopausal women.

5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.

PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.

Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

While PCOS might increase the risk of heart disease, there's not strong evidence to prove it causes earlier heart problems.

Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.

Finasteride may increase erectile dysfunction risk in patients with benign prostatic hyperplasia.

Obesity increases the risk of skin infections, inflammatory conditions, and melanoma, but not basal cell carcinoma.

PCOS increases the risk of heart disease and type 2 diabetes in women.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

PCOS affects women's health by increasing the risk of diabetes, heart disease, and reproductive issues.

Girls with PCOS during adolescence have a higher risk of developing type 2 diabetes, and early treatment can help manage this risk.

Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.

Higher TGF-β signaling may increase skin cancer risk in organ transplant recipients.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

A genetic region near the PAX1 gene is linked to a higher risk of scoliosis in females.

Oral contraceptives lower testosterone levels in women, especially those with certain genetic traits, and may be linked to increased breast cancer risk.

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Finasteride is a cost-effective option for treating BPH, reducing risk of urinary issues and surgery.